Selection of K65R mutation in HIV-2-infected patients receiving tenofovir-containing regimen

Antiviral Therapy

Volumn 9, Issue 4, 2004, Pages 635-636

  Damond, Florence ^a   Matheron, Sophie ^a   Peytavin, Gilles ^a   Campa, Pauline ^a   Taieb, Audrey ^b   Collin, Gilles ^a   Delaunay, Christophe ^a   Chêne, Geneviève ^b   Brun Vézinet, Françoise ^a   Descamps, Diane ^a  

^a BICHAT HOSPITAL   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ARGININE; LAMIVUDINE; LOPINAVIR; LYSINE; NELFINAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG SENSITIVITY; GENETIC SELECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; VIRUS MUTATION;

ADENINE; COHORT STUDIES; DRUG THERAPY, COMBINATION; FRANCE; GENOTYPE; HIV INFECTIONS; HIV-2; HUMANS; MUTATION; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; TIME FACTORS;

EID: 4344674318     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Wainberg MA, Miller MD, Quan Y, Salomon H, Mulato AS, Lamy PD, Margot NA, Anton KE & Cherrington JM. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antiviral Therapy 1999; 4:87-94.
2. Lanier E, Irlbeck D, Ross L, Gerondelis P, Underwood M, Parkin N, Shappey C & St Clair M. Prediction of NRTI options by linking reverse transcriptase genotype to phenotype breakpoints. 10th Conference on Retroviruses & Opportunistic Infections, 10-14 February 2003, Boston, Mass., USA. Abstract 586.
3. Parikh U, Koontz D, Hammond J, Bacheler L, Schinazi R, Meyer P, Scott W & Mellors J. K65R: a multi-nucleoside resistance mutation of low but increasing frequency. 12th International HIV Drug Resistance Workshop, 10-13 June 2003, Los Cabos, Mexico. Abstract 136.
4. Cundy KC, Sueoka C, Lynch GR, Griffin L, Lee WA & Shaw JP. Pharmacokinetics and bioavailability of the anti-human immunodeficiency virus nucleotide analog 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Antimicrobial Agents & Chemotherapy 1998; 42:687-690.
5. Margot NA, Isaacson E, McGowan I, Cheng AK, Schooley RT & Miller MD. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS 2002; 16:1227-1235.